LivingGLP1
parallel randomized trial

S003090

Design

Randomized
Start year
Treatment
1 weeks, follow-up 1 weeks
Countries
Japan (1 sites)
Sponsor
(not reported)
Eligibility
age over 18; type 2 diabetes over 3 months; noncritical inpatients; prior insulin under 10 units/day

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
modified itt
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Standard care or no added treatment
Basal plus (glargine)
insulin glargine once daily titrated to fasting glucose 100 to 140 mg/dL plus correction regular insulin before meals; oral agents stopped; lifestyle: not reported27
A2Dulaglutide 0.75 mg subcutaneous once weekly
Basal plus with dulaglutide
insulin glargine plus correction regular insulin before meals; oral agents stopped; lifestyle: not reported27

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticStandard care or no added treatment
A1
Dulaglutide 0.75 mg subcutaneous once weekly
A2
agemean (years)70.170.9
agesd (years)1413
bmimean (kg/m2)24.625.1
bmisd (kg/m2)5.76.7
diabetes durationmean (years)10.18.7
diabetes durationsd (years)8.89.4
hba1cmean (percent)8.08.2
hba1csd (percent)1.91.7
other malen1815
other malepercent6756

Analyses this trial contributes to

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Level 2 or 3 hypoglycemia (participants) (6 lines; O04)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events9 / 27not stated; modified itt; R0025350:Table 3
A1events1 / 27not stated; modified itt; R0025350:Table 3
A1events6 / 27not stated; modified itt; R0025350:Table 3
A2events3 / 27not stated; modified itt; R0025350:Table 3
A2events0 / 27not stated; modified itt; R0025350:Table 3
A2events1 / 27not stated; modified itt; R0025350:Table 3